Brevan Howard Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Brevan Howard Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,201	Closed	-$475K	–	1774
2025 Q3	$475K	Sell	25,201 -18,733	-43%	-$295K	﹤0.01%	1317
2025 Q2	$616K	Buy	43,934 +3,316	+8%	+$46.5K	﹤0.01%	1264
2025 Q1	$635K	Buy	+40,618	New	+$572K	0.01%	659
2024 Q4	–	Sell	-35,147	Closed	-$327K	–	1032
2024 Q3	$327K	Sell	35,147 -52,683	-60%	-$520K	﹤0.01%	817
2024 Q2	$817K	Buy	+87,830	New	+$794K	0.01%	437
2024 Q1	–	Sell	-51,442	Closed	-$166K	–	1004
2023 Q4	$166K	Buy	+51,442	New	+$140K	﹤0.01%	904

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Brevan Howard Capital Management's ARQT Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q4 2025, closing a stake of 25,201 shares — an estimated $475K sold.

Brevan Howard Capital Management first reported a position in ARQT in Q4 2023 and held it in 6 quarters. The position peaked at $817K in Q2 2024. 283 funds tracked by Wall St. Rank hold ARQT as of Q4 2025.

Brevan Howard Capital Management reported no remaining Arcutis Biotherapeutics position as of Q4 2025 after selling out during the quarter.
Brevan Howard Capital Management sold 25,201 Arcutis Biotherapeutics shares in Q4 2025, an estimated $475K.
Brevan Howard Capital Management first reported a position in Arcutis Biotherapeutics in Q4 2023 and held it in 6 quarters.
Brevan Howard Capital Management's Arcutis Biotherapeutics position peaked at $817K in Q2 2024.
283 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.